相关实验视频

Updated: May 13, 2025

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

鼠肉瘤 (RAS) - 针对蛋白质的合成细胞透作为抗癌生物材料

Gookjin Yoon¹, Jinsook Suh¹, Beom Soo Jo^1,2

¹Department of Dental Regenerative Biotechnology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul 03080, Republic of Korea.

Biomaterials research

|April 16, 2025

概括

一种新的大鼠肉瘤 (RAS) 结合 (RBP) 通过破坏RAS-RAF-ERK1/2通路,有效地抑制癌细胞的增殖和转移. 这种治疗生物材料显示出治疗RAS突变癌症的巨大潜力.

科学领域:

生物化学生物化学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

生物活性被探索用于癌症治疗,向像RAS-RAF-ERK1/2.2.这样的途径.
在人类癌症中,RAS-RAF-ERK1/2通路至关重要,使其成为药物开发的关键目标.
具有KRAS突变的三阴性乳腺癌系的MDA-MB-231细胞通常具有耐药性.

研究的目的:

评估合成大鼠肉瘤 (RAS) 结合 (RBP) 的抗癌潜力.
调查RBP在破坏RAS-RAF相互作用和下游信号的作用机制.
评估RBP在抑制瘤生长和转移的实验室和体内疗效.

主要方法:

使用MDA-MB-231癌细胞进行体外研究,以评估扩散,ERK1/2酸化,迁移和入侵.
使用蛋和老鼠异种移植模型进行体内研究,以评估瘤生长和侵入性.
瘤组织的组织病理学分析,以评估免疫细胞透和Ki-67表达.

主要成果:

通过破坏RAS-RAF相互作用,RBP显著抑制了扩散和ERK1/2酸化.
RBP抑制了癌细胞的迁移和入侵,表明了抗转移潜力.
在体内模型显示,RBP阻止了瘤生长和侵入性,增加了免疫透和减少了Ki-67的表达.

结论:

RBP是一种强大的治疗生物材料,可以有效地阻碍RAS突变癌症的进展和转移.
RBP破坏RAS-RAF-ERK1/2通路的能力为抗癌药物开发提供了一个有前途的战略.
RBP在体外和体外表现出显著的抗瘤活性,突出显示了其治疗潜力.

更多相关视频

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...